亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation with next-generation sequencing.

医学 伦瓦提尼 无容量 彭布罗利珠单抗 内科学 肿瘤科 癌症 索拉非尼 微卫星不稳定性 不利影响 卡波扎尼布 进行性疾病 胃肠病学 疾病 免疫疗法 基因 肝细胞癌 化学 等位基因 微卫星 生物化学
作者
Jianzhen Lin,Weiwei Shi,Songhui Zhao,Jinwei Hu,Zheng Hou,Ming Yao,Gungwei Chrin,Jie Pan,Ke Hu,Lin Zhao,Milind Javle,Kai Wang,Haitao Zhao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (4_suppl): 500-500 被引量:47
标识
DOI:10.1200/jco.2018.36.4_suppl.500
摘要

500 Background: Lenvatinib (Len) is a multikinase inhibitor targeting VEGFR 1-3, FGFR 1-4 and other kinases. Pembrolizumab (Pem) and nivolumab (Nivo) are antibodies inhibiting programmed cell death 1 (PD-1) and reactivate T-cell cytotoxic effect. Len plus PD-1 inhibitors have shown promising results in treating various solid tumors. The role of this combination in ICC is undefined. Methods: 14 ICC pts (median age 49 years, range 34-68; 7 males and 7 females) with treatment of enrolled in a single center, observational study of Len plus Pem/Nivo. Objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) were measured according to RECIST 1.1. Next generation sequencing (NGS) with deep coverage on 450 cancer genes and whole exome sequencing were performed in 7 pts to detect all classes of genomic alterations, tumor mutational burden (TMB) and microsatellite instability (MSI) status. Results: All 14 pts had > = 2 prior anticancer therapy with clinical stage IV. ORR was 21.4% with 3 pts achieved partial response (PR), DCR was 92.9% and clinical benefit rate (ORR + durable stable disease > = 5 months) was 64.3%. Median PFS was 5.9 months (95% CI: 4.2-6.2). The most common adverse events (AEs) included hypertension, aminotransferase elevation and fatigue. The grade-3 AEs were occurred at 14% while no grade-4 AE was observed. The most altered genes in the 7 sequenced tumors were IDH1 (3 pts), ARID1A (3 pts), PIK3CA (3 pts), TP53 (2 pts) and BAP1 (2 pts). 4 out of the 7 pts had high TMB ( > 12 mut/Mb) and all responded to Len plus Pem/Nivo with 2 PR. One pt with low TMB and FGFR2 mutation had a response of 27% decreased target lesion. Two low TMB pts were progressed, including one with FGFR2 rearrangement. A responder harbored a 399 bp deletion on MLH1, and was identified as MSI-H. More data will be presented. Conclusions: Our study preliminarily indicates that combining Len with PD-1 inhibitors results in promising efficacy in advanced ICC. High TMB from 450-gene NGS panel was strongly associated with a better therapeutic response.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
浮云发布了新的文献求助10
2秒前
2秒前
13秒前
19秒前
复杂曼荷完成签到,获得积分10
21秒前
may完成签到 ,获得积分10
23秒前
31秒前
32秒前
英俊的铭的应助被邓倩采纳,获得10
32秒前
Maestro_S的应助被呵呵采纳,获得10
36秒前
00hello00发布了新的文献求助10
39秒前
43秒前
46秒前
仁爱的鞋子完成签到,获得积分10
1分钟前
安详老鼠完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Shu完成签到,获得积分10
1分钟前
刻苦的煎蛋完成签到,获得积分10
1分钟前
庾傀斗发布了新的文献求助10
1分钟前
ssgg完成签到,获得积分10
1分钟前
辛勤诗兰完成签到,获得积分10
1分钟前
1分钟前
不爱写论文完成签到,获得积分10
1分钟前
HaoZhang发布了新的文献求助10
1分钟前
1分钟前
Lynee完成签到,获得积分10
1分钟前
清脆妙梦完成签到,获得积分10
1分钟前
sugar发布了新的文献求助10
1分钟前
小辣椒完成签到,获得积分10
1分钟前
HaoZhang完成签到,获得积分20
1分钟前
尊敬康乃馨完成签到,获得积分10
1分钟前
初景发布了新的文献求助10
1分钟前
zhaodan完成签到,获得积分10
1分钟前
思源的应助被sugar采纳,获得30
1分钟前
贪玩芝完成签到 ,获得积分10
1分钟前
guyuzheng完成签到,获得积分10
2分钟前
爱听歌谷蓝完成签到,获得积分10
2分钟前
魔幻的芳完成签到,获得积分10
2分钟前
123啊完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195111
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872823
捐赠科研通 7794997
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609